<DOC>
	<DOC>NCT00166452</DOC>
	<brief_summary>The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).</brief_summary>
	<brief_title>A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<criteria>1. Age &gt; or = to 18 years 2. Signed consent form 3. A diagnosis of CRPS type I for at least oneyear duration with unilateral involvement of a distal limb 4. CRPS pain intensity score at least 4 on an 11point PINRS 5. Measurable sural, median sensory, median motor and peroneal motor nerve conductions 6. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting the study drug. They must agree to use adequate contraceptive methods not including steroidbased contraceptives. They must also agree to have pregnancy tests every 4 weeks while on the study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>